Backers included new investors New Ventures III, as well existing investors. In conjunction with the funding, Mark Finn, Founding Partner at New Ventures III, joined Enterin’s Board of Directors.
The company intends to use the funds to complete the ongoing Phase 2 study in PD, further expand its understanding of the role of alpha-synuclein (aS) in the pathology of PD and begin to explore other indications.
Led by Michael Zasloff, M.D. Ph.D., Founder, Chairman and CEO, and and Denise Barbut, M.D. F.R.C.P., Co-Founder, President and Chief Medical Officer, Enterin develops a novel drug that repairs the dysfunctional gut-brain axis in patients with neurodegenerative disease. The lead compound, ENT-01, displaces membrane-bound alpha-synuclein (αS) aggregates from nerve cells in the enteric nervous system in order to improve neural signaling between the gut and the brain in preclinical models of Parkinson’s disease. The company is now progressing ENT-01 through clinical trials aimed at reversing the constipation of Parkinson’s disease.
FinSMEs
17/07/2017